Pozen Inc: (NASD: POZN)
$4.93
0.03 (0.61%)
Volume 111,364
May 23 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 4.89 - 5.02 |
| 52wk Low - High | 4.26 - 7.55 |
| Previous Close | 4.90 |
| Avg. Volume | 228,135 |
| Industry | MED-DRUGS |
| Market Cap | 148.70 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.38 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.34 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
106 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.34 |
| Current Quarter Estimate | -0.21 |
| Most Accurate Estimate | -0.21 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.75 |
| Expected Earnings Growth | NA |
Company Description
Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.21 | -0.21 | -0.34 | 0.18 |
| Number of Estimates | 3 | 3 | 3 | 2 |
| Low Estimate | -0.22 | -0.21 | -0.81 | 0.18 |
| High Estimate | -0.19 | -0.20 | 0.47 | NA |
| Year Ago EPS | -0.17 | -0.19 | -0.84 | -0.34 |
| EPS Growth | -21.57% | -8.77% | 59.92% | 153.47% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| POZEN INC | POZN | 4.90 | |
|
| JAZZ PHARMACEUT | JAZZ | 61.53 | |
|
| SALIX PHARM-LTD | SLXP | 59.47 | |
|
| SANTARUS INC | SNTS | 22.28 | |
|
| USANA HLTH SCI | USNA | 68.14 | |
|
| CATALYST PHARMA | CPRX | 0.85 | |
|
| CELL THERAPEUT | CTIC | 1.29 | |
|
| CUBIST PHARM | CBST | 56.11 | |
|
| ELAN CP PLC ADR | ELN | 12.04 | |
|
| INFINITY PHARMA | INFI | 23.12 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.75 |
| Sales | 5 |
| Net Income | -23 |
| Price/Earnings | NA |
| Price/Book | 1.88 |
| Price/Cash Flow | NA |
| Price/Sales | 27.16 |
News
5 Stocks Under $10 Set to Soar - TheStreet.com
Apr 18, 2013
Stocks Hitting 52-Week Lows - Benzinga
Apr 5, 2013
POZEN Submits NDA for PA32540/PA8140 - Benzinga
Mar 27, 2013
European Patent Office Maintains POZEN PA/VIMOVO Patent - Benzinga
Mar 12, 2013
Earnings Scheduled For March 6, 2013 - Benzinga
Mar 6, 2013
Zacks Reiterates Outperform Rating, $9.50 PT on POZEN on PA-325/40 Product Data Presentations - Benzinga
Mar 6, 2013
POZEN to Offer Phase 3 Data on PA32540 at International Stroke Conference - Benzinga
Feb 8, 2013
Cheap, Quickly Growing Stocks for 2013 (Last Part) - TheMotleyFool
Jan 4, 2013
Broker Recommendations
| Current ABR | 1.25 |
| ABR (Last Week) | 1.25 |
| # of recs in ABR | 4 |
| Average Target Price | 9.06 |
| Industry Rank by ABR | 106 out of 265 |
| Rank in Industry | 15 out of 93 |
